Global Respiratory Drugs Market Report: Analysis and Forecast 2018-2022 - A Key Driver is the Increase in Incidence & Prevalence of Different Types of Respiratory Diseases - ResearchAndMarkets.com

The "Global Respiratory Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The respiratory drugs market will register a CAGR of almost 6% by 2022.

The high cost of respiratory disease management is expected to drive growth in the respiratory drugs market. The high cost of respiratory disease management has led the organizations such as the Lung Foundation Australia to demand support and funding from the government to reduce the cost.

Increase in Incidence & Prevalence of Different Types of Respiratory Diseases

Globally, respiratory diseases are a key cause of mortality and disease burden. Numerous types of respiratory diseases are on the rise, thereby pushing growth in the respiratory drugs market.

Patient Non-adherence Treatment

Non-adherence to treatment is particularly problematic for asthma and COPD disease management due to heterogeneous patient population. Device switching symptoms variability, and comorbidities are responsible for suboptimal adherence rates.

Competitive Landscape

With the presence of a considerable number of companies, this market appears to be fragmented. Several respiratory drug companies are focused on evolving new respiratory drugs with the entry of biologics and biosimilars for promising options for respiratory disease management.

Market Trends

• High Cost of Respiratory Disease Management
• Availability of Biologics and Biosimilars
• High Use of Complementary and Alternative Medicines
• Entry of Generics

Key Players

• AstraZeneca
• GlaxoSmithKline
• Merck
• Novartis

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Research Methodology

4. Market Landscape

5. Pipeline Analysis

6. Market Sizing

7. Five Forces Analysis

8. Market Segmentation by Type of Respiratory Disease

9. Customer Landscape

10. Regional Landscape

11. Decision Framework

12. Drivers and Challenges

13. Market Trends

14. Vendor Landscape

15. Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/pk8jkn/global?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181211005613/en/

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs